ABSTRACT
Objective@#To investigate the efficacy and safety of conbercept injection in the treatment of exudative age-related macular degeneration(AMD).@*Methods@#From October 2016 to October 2017, 300 patients(300 eyes) with exudative AMD in Linfen Central Hospital were divided into two groups according to the random number table method.The study group(150 cases and 150 eyes) received intravitreal injection of 0.05 mL of conbercept once a month for 3 months.The control group(150 cases and 150 eyes) received conservative treatment.All patients were followed up for 12 months after treatment.The differences of BCVA, CMT, QOL, clinical efficacy and complications between the two groups were compared.@*Results@#BCVA was significantly increased and CMT was significantly decreased in the two groups after treatment, and BCVA was higher in the study group at 9 months [(0.55±0.11) vs.(0.51±0.15)], 12 months [(0.59±0.21) vs.(0.53±0.11)] after treatment compared with the control group(t=2.634, 3.010, all P<0.05), and CMT was lower in the study group at 1-12 months after treatment(t=5.321, 20.035, 25.593, 22.456, 26.326, 27.005, all P<0.05). At the last follow-up, the distant vision, regulating ability, reading and fine work scores in the study group were (55.27±8.24)points, (30.21±5.20)points, (20.15±5.01)points, (47.02±12.34)points, respectively, which were better than those in the control group[(50.21±6.35)points, (25.34±4.17)points, (16.24±3.27)points, (40.25±9.25)points](t=6.352, 5.324, 6.392, 8.251, all P<0.05). The total effective rate of the study group[88.00%(132/150)] was higher than that of the control group[76.67%(115/150)](χ2=6.623, P<0.05). There were no serious complications in the two groups.@*Conclusion@#Conbercept injection can significantly improve the eyesight of exudative AMD patients, improve the quality of life, it is safe and reliable, and its treatment effect for AMD is better than traditional conservative treatment.
ABSTRACT
Objective To investigate the efficacy and safety of conbercept injection in the treatment of exudative age－related macular degeneration ( AMD).Methods From October 2016 to October 2017,300 patients (300 eyes) with exudative AMD in Linfen Central Hospital were divided into two groups according to the random number table method.The study group (150 cases and 150 eyes ) received intravitreal injection of 0.05 mL of conbercept once a month for 3 months.The control group(150 cases and 150 eyes) received conservative treatment. All patients were followed up for 12 months after treatment.The differences of BCVA ,CMT,QOL,clinical efficacy and complications between the two groups were compared.Results BCVA was significantly increased and CMT was significantly decreased in the two groups after treatment,and BCVA was higher in the study group at 9 months [(0.55 ± 0.11) vs.(0.51 ±0.15)],12 months [(0.59 ±0.21) vs.(0.53 ±0.11)] after treatment compared with the control group(t＝2.634,3.010,all P＜0.05),and CMT was lower in the study group at 1－12 months after treatment(t＝5.321, 20.035,25.593,22.456,26.326,27.005,all P＜0.05).At the last follow－up,the distant vision,regulating ability, reading and fine work scores in the study group were (55.27 ±8.24) points,(30.21 ±5.20) points,(20.15 ± 5.01)points,(47.02 ±12.34) points,respectively, which were better than those in the control group [( 50.21 ± 6.35)points,(25.34 ±4.17)points,(16.24 ±3.27)points,(40.25 ±9.25) points](t＝6.352,5.324,6.392,8.251, all P＜0.05).The total effective rate of the study group [88.00%(132／150)] was higher than that of the control group[76.67%(115／150)](χ2 ＝6.623,P＜0.05).There were no serious complications in the two groups.Conclusion Conbercept injection can significantly improve the eyesight of exudative AMD patients ,improve the quality of life,it is safe and reliable,and its treatment effect for AMD is better than traditional conservative treatment .